Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication October 28, 2021
- Revision received March 9, 2022
- Published online November 1, 2022.
Article Versions
- previous version (March 17, 2022 - 12:57).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Louise Emmett1,2,3,
- Nathan Papa4,
- James Buteau5,6,
- Bao Ho1,
- Victor Liu1,
- Matthew Roberts7,
- James Thompson8,
- Dan Moon9,
- Gemma Sheehan-Dare1,
- Omar Alghazo9,
- Shikha Agrawal1,
- Declan Murphy9,
- Phillip Stricker10,11,
- Thomas A. Hope12 and
- Michael S. Hofman5,6,13
- 1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
- 2Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
- 3St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
- 4School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia;
- 5Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
- 6Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Centre, Melbourne, Victoria, Australia;
- 7Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia;
- 8Department of Urology, St. George Hospital, Kogarah New South Wales, Australia;
- 9Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
- 10Department of Urology, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
- 11St. Vincent’s Prostate Cancer Centre, Darlinghurst, New South Wales, Australia;
- 12Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; and
- 13Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
- For correspondence or reprints, contact Louise Emmett (louise.emmett{at}svha.org.au).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- The PRIMARY Score: Present and Future
- Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study
- Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard
- The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study
- Diagnostic Performance of 68Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer
- Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
- A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study
- 68Ga-PSMA PET/CT and Prostate Cancer Diagnosis: Which SUVmax Value?